Kernel and Cybin Inc. announced pilot results from a Cybin-sponsored feasibility study evaluating Kernel's quantitative neuroimaging technology, Flow, to measure cortical hemodynamics while experiencing an altered state of consciousness. Preliminary data from the piloting suggested that ketamine-induced changes in functional connectivity persisted for several days after administration. Kernel Flow successfully measured the neuro-effect of
ketamine over 11 days (baseline at Days 1-5, dosing at Day 6, follow-up Days 7-11), and confirmed changes in functional connectivity that are consistent with current scientific research(1). The piloting was conducted to ensure the efficiency of the feasibility study design. Participants in the pilot received either a low dose of ketamine and/or a placebo while wearing the Flow headset. The feasibility study received U.S. Food and Drug Administration ("FDA") Investigational New Drug authorization in October 2021 and U.S. Institutional Review Board approval in January 2022.